Skip to main content
. 2020 Nov 13;9(11):3655. doi: 10.3390/jcm9113655

Figure 1.

Figure 1

Molecular targets of novel tyrosine kinase inhibitors (TKIs) in neuroendocrine tumors (NETs). FGFR: fibroblast growth factor receptor; CSF-1R: colony stimulating factor 1 receptor; VEGFR: vascular endothelial growth factor receptor; PDGFR: platelet-derived growth factor.